T7 Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
T7 Therapeutics, Inc. - overview
Established
2021
Location
Wilmington, DE, US
Primary Industry
Biotechnology
About
Based in Delaware, US, and founded in 2021, T7 Therapeutics, Inc operates as a biotechnology company that develops monoclonal antibodies for the treatment of autoimmune diseases. In November 2021, T7 Therapeutics, Inc. raised venture funding from new investor TVM Capital Life Science. As of 2021, the company is led by its CEO Caroline Fortier.
The firm conducts research and development to create biotechnology-based drugs to treat illnesses of the immune system.
Current Investors
TVM Capital Life Science
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Pharmaceutical Research & Development
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.